Advertisement

Intensive Care Medicine

, Volume 30, Issue 5, pp 994–994 | Cite as

A blind clinical evaluation committee should, in theory, make data of a randomized clinical trial stronger, not weaker

  • J. CarletEmail author
Correspondence

Keywords

Placebo Endpoint Placebo Group Treated Patient Septic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Dhainaut JF, Laterre PR, LaRosa SP, Levy H, Garber GE, Heiselman D, Kinasewitz GT, Light RB, Morris P, Schein R, Sollet JP, Bates BM, Utterback BG, Maki D (2003) The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS) : role, methodology and results. Crit Care Med 31:2291–2301CrossRefPubMedGoogle Scholar
  2. 2.
    Sprung CL, Finch RG , Thijs LG, Glauser MP (1996) International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee. Crit Care Med 24:1441–1447CrossRefPubMedGoogle Scholar
  3. 3.
    Panacek EA, Marshall J, Albertsen T et al. (2000) Effect of a clinical evaluation committee explicit review on classification of patients and prediction of mortality in the MONARCS sepsis trial. Crit Care Med 28:A197, Abst 609Google Scholar
  4. 4.
    Ely WE, Angus DC, Williams MD Bates B, Qualy R, Bernard GR (2003) Drotrecogin alfa (activated) treatment of older patients with severe sepsis. CID 37:187–95CrossRefGoogle Scholar
  5. 5.
    Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL (2003) Recombinant Human Activated protein C worldwide evaluation in sepsis (PROWESS) study group. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 29:894–903PubMedGoogle Scholar
  6. 6.
    Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B (1995) Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multi-center prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 274:968–974PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Fondation Hopital Saint-JosephParisFrance

Personalised recommendations